SBIR/STTR Research Award

A simple device for office evaluation of tubal patency during the workup for infertility.

Award identifier 6a99278a2f0c1078cfdc77f5159aedc57bc39e7466fdb90b857de22a961fc068Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$306,778

Program and phase

SBIR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
OryGyn Medical Devices, LLC
Proposal award date
2025-08-01
Contract end date
2026-07-31
UEI
JT47FJ6MR7Y3
Solicitation number
PA24-245
Topic code
NICHD

Research abstract

PROJECT SUMMARY OryGyn Medical Devices, LLC is developing a novel and highly innovative Tubal Selective Delivery System (TSDS) designed to safely and selectively administer fluids, foams, or gels to the fallopian tubes through a nonsurgical transcervical approach. The basic work-up of infertility includes evaluation of whether the tubes are open to passage of eggs and sperm (fallopian tube patency) using a hysterosalpingogram, a radiologic study that requires referral to a specialist and exposure to ionizing radiation. The TSDS would provide clinicians with a simple and convenient office-based option for evaluation of tubal occlusion without referral to specialists. The worldwide prevalence of infertility, defined as failure to conceive after more than 12 months of unprotected intercourse, is approximately 8%–12% and decreased ability to conceive - subfertility - affects an additional 15% of couples. The TSDS would increase convenience for patients and decrease costs associated with evaluation of this problem. In this Phase I proposal, we propose the following objectives: Aim 1: Compare characteristics of internal and external frame designs to identify and manufacture a second generation FertChx TSDS; Aim 2: Demonstrate the performance characteristics of FertChx using a simulated uterine model to establish benchmarks for a clinical testing. This Phase I project will characterize the performance of a lead device and provide documentation of the good manufacturing practices (GMP) required for production of devices for a clinical trial. Successful completion of Phase I will support submission of a Phase II proposal to complete a clinical trial evaluating safety and efficacy of the device for verification of tubal patency and necessary components for regulatory review. Together, the Phase I and II programs will support our business objective of 510(K) approval of the lead TSDS device for use as an office-based device for tubal patency evaluation.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.